Cargando…

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER(+ )disease

Loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma protein) pathway are common in breast cancer. Consequently, inhibition of this pathway is an attractive therapeutic strategy, but results from clinical trials of CDK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sutherland, Robert L, Musgrove, Elizabeth A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815549/ https://www.ncbi.nlm.nih.gov/pubmed/20067604 http://dx.doi.org/10.1186/bcr2454

Ejemplares similares

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER(+) breast cancer with mitotic aberrations
por: Soria-Bretones, Isabel, et al.
Publicado: (2022)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
por: Formisano, Luigi, et al.
Publicado: (2019)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
por: Jin, Xi, et al.
Publicado: (2020)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
por: Lin, Chang-Ching, et al.
Publicado: (2023)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
por: Akhade, Amol, et al.
Publicado: (2022)

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models
por: Sutherland, Robert L, et al.
Publicado: (2002)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
por: Rodriguez, María Jimena, et al.
Publicado: (2023)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Therapeutic potential of CDK11 in cancer
por: Blazek, Dalibor
Publicado: (2023)

Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer
por: Finnegan, Ryan M., et al.
Publicado: (2022)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors
por: Czeleń, Przemysław, et al.
Publicado: (2022)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Al-Qasem, Abeer J., et al.
Publicado: (2021)

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer
por: Petrossian, Karineh, et al.
Publicado: (2018)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
por: Kaminska, Kamila, et al.
Publicado: (2021)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023)

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
por: Lindeman, Geoffrey J., et al.
Publicado: (2022)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup
por: Alles, M. Chehani, et al.
Publicado: (2009)

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
por: MAHGOUB, T., et al.
Publicado: (2015)

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
por: Liang, Xuan-Bing, et al.
Publicado: (2023)

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
por: Main, Sasha C., et al.
Publicado: (2022)

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
por: Kubeczko, Marcin, et al.
Publicado: (2023)

Cyclin E1-CDK 2, a potential anticancer target
por: Fang, Dongdong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e0avbs82ui5014mhnh91dmmeug